LAS VEGAS, Nov. 08, 2018 -- InvestorsHub NewsWire -- THC
Therapeutics Inc (OTC: MBLC) is a forward-thinking
publicly traded Health and Wellness company in the cannabis
industry that has "Better Health through the Science of Nature" as
their guiding statement. Today announced that they will focus their
operations on the Cannabis industry and their soon-to-be issued
patent for “The dHydronator®.”
THC Therapeutics developed a sanitizing herb dryer, The
dHydronator®, with multiple design, function, and
usages. The Company anticipates that the patent will be issued
within the next two months. This innovative, laboratory-proven
product is specifically designed for drying and sanitizing freshly
harvested Cannabis, herbs, teas, etc. The
dHydronator® can reduce moisture content of
Cannabis to 10% in only 10-14 hours. Traditional Cannabis drying
times take up to two weeks.
Another one of the major aspects of The
dHydronator® is that it has been proven to destroy
harmful surface contaminants & pathogens. With our built-in,
SanitiZen® technology, we are able to reduce
the microbial load from failing in cannabis and bring the
contaminants down to passing levels.
The dHydronator® has been tested by two
independent laboratories the last being
DigiPath https://digipath.com/ (OTCQB: DIGP), testing covered over 6
strains and 9 independent tests to confirm the findings. The
strains tested were Lucy Diamond, Cotton Candy, Blue Dream, Kings
Cut, Pot of Gold and Diablo. Our SanitiZen technology brought the
failing TAC (total aerobic count) from over 300,000 down to 78,000.
The optimal drying time was determined to be 10-14 hours, but may
vary by region and ambient humidity. By far the most surprising
data from the testing was the potency of the cannabis after
exposure to the dHydronator. Over the 9 tests and 6 strains, there
was a 4% average increase of THC-A*.
*See complete results at https://THCtherapeutics.com/index.php/dhydronator/
These results exceeded our expectations and were surprising even
to us. We cannot be be more pleased with what the
dHydronator® can do.
In late July of 2018, the Company’s patent attorney received
notice from the United States Patent and Trademark Office (the
“USPTO”) that the USPTO would be allowing all 20 of our patent
claims for The dHydronator®. In light of this
development, and after analyzing the current regulatory environment
regarding companies focused on investing in cryptographic tokens
and other digital assets, the Company then determined that it would
refocus its efforts on developing the soon-to-be patented
dHydronator®, and the Company changed its name to “THC
Therapeutics, Inc.”
The Company also filed a Form 10 Registration Statement with the
U.S. Securities and Exchange Commission on October 22, 2018. The
Company intends to be a fully reporting issuer on December 21,
2018, which is 60 days from the date of the Form 10 filing.
See- https://www.sec.gov/Archives/edgar/data/1404935/000147793218004955/mblc_1012ga.htm
In light of the Company’s name change and new business focus,
the Company will be filing a notification with FINRA for a ticker
symbol and name change
Brandon Romanek, our Founder and CEO, stated, “I could not be
more elated that the US patent office has accepted ALL 20 of our
claims for The dHydronator®. We filed for patent
protection well over 2 years ago, but we did not expect to receive
such broad protection on our intellectual property. Many experts in
the cannabis industry liked our technology; however, they expressed
serious doubts that we would receive any type of patent protection—
much less the broad protection afforded by all 20 of our
claims.”
Romanek further commented, “Today THC Therapeutics is a much
stronger company than we were just 8 months ago. Then, we only had
a pending patent, with few other assets. Since then we have
invested in Blockchain-related companies. We issued restricted
shares to those companies and have the right to receive equity
and/or tokens from those companies. https://www.impactppa.com and https://www.robotcache.com/ intend to have a
token creation event by the first quarter of next year, and the
Company expects to receive tokens in connection with them. I am a
firm believer in Blockchain and Crypto, and plan to stay on top of
regulatory and market changes. I am pleased with the progress
we have made since we went public in January of 2017 via reverse
merger. We have taken solid steps to turn our vision into
reality.”
The Company intends to provide information regarding further
updates on the patent status and its plans moving forward in future
press releases.
About THC Therapeutics
THC Therapeutics, Inc. (OTC: MBLC) is focused on developing The
dHydronator®, a sanitizing herb dryer. The main function
of The dHydronator® is to greatly accelerate the
drying time of a herb while sanitizing it. The
dHydronator® can be used to dry a variety of herbs,
and it has been specifically tested for use with cannabis, and it
will reduce the drying time for cannabis from 10-14 days to less
than 14 hours. The Company plans to also focus some of its
operations on participation in cannabis testing lab facilities and
developing personal wellness centers, as well as investigating
other potentially disruptive technologies The Company is seeking
partnerships, mergers and acquisitions in the Cannabis, Health and
Wellness industries in the United States & Canada. For more
information, visit THCtherapeutics.com.
Follow Brandon Romanek on Twitter:
Twitter @BrandonRomanek
Follow THC Therapeutics on Facebook
https://www.facebook.com/THCtherapetuics
About Digipath, Inc.
Digipath,
Inc. supports the cannabis industry's
best practices for reliable testing, cannabis education and
training, and brings unbiased cannabis news coverage to the
cannabis industry. Digipath
Labs provides pharmaceutical-grade
analysis and testing to the cannabis industry to ensure producers,
consumers, and patients know exactly what is in the cannabis they
ingest and to help maximize the quality of its client's products
through analysis, research, development, and
standardization.
Forward-Looking Statements Disclosure
This press release may contain "forward-looking statements"
within the meaning of the federal securities laws. In this context,
forward-looking statements may address the Company's expected
future business and financial performance, and often contain words
such as "anticipates," "beliefs," "estimates," "expects,"
"intends," " plans," "seeks," "will," and other terms with similar
meaning. These forward-looking statements by their nature address
matters that are, to different degrees, uncertain. Although the
Company believes that the assumptions upon which its
forward-looking statements based are reasonable, it can provide no
assurances that these assumptions will prove to be correct. All
forward-looking statements in this press release are expressly
qualified by such cautionary statements, risk, and uncertainties,
and by reference to the underlying assumptions.
PR & Media Contact:
(702) 602-8422
info@THCtherapeutics.com
Grafico Azioni THC Therapeutics (CE) (USOTC:THCT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni THC Therapeutics (CE) (USOTC:THCT)
Storico
Da Lug 2023 a Lug 2024